Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19

Thrombosis is a known complication of SARS-CoV-2 infection, particularly within a severely symptomatic subset of patients with COVID-19 disease, in whom an aggressive host immune response leads to cytokine storm syndrome (CSS). The incidence of thrombotic events coinciding with CSS may contribute to...

Descripción completa

Detalles Bibliográficos
Autores principales: Khimani, Faria, Wolf, Adam J., Yoon, Braian, Blancke, Amy, Gerhart, Coltin, Endsley, Dakota, Dougherty, Alleyna, Ray, Anish K., Yango, Angelito F., Flynn, Stuart D., Lip, Gregory Y.H., Gonzalez, Stevan A., Sathyamoorthy, Mohanakrishnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650687/
http://dx.doi.org/10.1016/j.tru.2022.100126
Descripción
Sumario:Thrombosis is a known complication of SARS-CoV-2 infection, particularly within a severely symptomatic subset of patients with COVID-19 disease, in whom an aggressive host immune response leads to cytokine storm syndrome (CSS). The incidence of thrombotic events coinciding with CSS may contribute to the severe morbidity and mortality observed in association with COVID-19. This review provides an overview of pharmacologic approaches based upon an emerging understanding of the mechanisms responsible for thrombosis across a spectrum of COVID-19 disease involving an interplay between immunologic and pro-thrombotic events, including endothelial injury, platelet activation, altered coagulation pathways, and impaired fibrinolysis.

Ejemplares similares